ARDSLEY, N.Y.--(BUSINESS WIRE)--
- Framing OFF Through Art℠ gallery illustrates individuals’ experience with OFF periods
- New research on OFF periods to be presented at conference plenary session
Acorda Therapeutics, Inc. (ACOR) today announced that it will debut an art gallery inspired by people with Parkinson’s (PwP) at the 5th World Parkinson Congress (WPC) in Kyoto, Japan. The six pieces of art, ranging from acrylic sculptures to oil paintings, are the centerpiece of Acorda’s Framing OFF Through Art initiative. OFF periods are the re-emergence of Parkinson’s symptoms, and affect approximately 40 percent of the one million people living with Parkinson’s in the U.S. This initiative builds on Acorda’s “Live Well. Do Tell.℠” program; its goal is to help initiate effective conversations about OFF periods between PwPs and their healthcare professionals.
Framing OFF Through Art uses the power of art to help PwPs better identify and articulate their experiences with OFF periods. It includes a series of artworks inspired by the personal stories of people with Parkinson’s and their care partners. The artworks were created by artists who also have a personal connection to the disease. Conference attendees can view the gallery and learn more at Acorda’s booth, #209.
“Research has consistently shown that OFF periods are among the most common issues for people living with Parkinson’s disease,” said Ron Cohen, M.D., Acorda’s President and CEO. “This re-emergence of Parkinson’s symptoms can occur unexpectedly, up to several times a day, despite daily medication regimens; this causes enormous disruption and distress to the people who experience this. In addition, each person’s experience with OFF periods is unique and can be difficult to describe. We believe that people with Parkinson’s will be able to see aspects of their own experiences with Parkinson’s and OFF periods in these works of art, and use this as an opportunity to discuss their symptoms with their healthcare team.”
In addition, new research on the nature and diversity of Parkinson’s disease will be presented by Connie Marras, M.D., Ph.D., associate professor at University Health Network, University of Toronto, during the Morning Plenary on June 6, 2019, at 9:30 am JST. Dr. Marras will also be presenting research around OFF periods during the poster tour on June 5, 2019. The research on OFF periods was supported by an Acorda Therapeutics research grant, administered by The Michael J. Fox Foundation for Parkinson's Research.
Acorda is also a gold sponsor of the WPC 2019 Art Walk – a series of art, live music and dance exhibits. One of these exhibits, “Soaring with Hope for PD,” features an installation of 15,000 origami cranes with messages of hope from 39 countries.
About “Live Well. Do Tell.”
“Live Well. Do Tell.” is an initiative created by Acorda with input from a multi-disciplinary Steering Committee of Parkinson’s community leaders. The goal of the program is to develop tools to address communication gaps among people with Parkinson’s, their care partners and their healthcare professionals.
The Steering Committee included people with Parkinson’s, care partners, movement disorder specialists, a nurse practitioner and representatives from key advocacy groups, including the American Parkinson’s Disease Association, Caregiver Action Network, Davis Phinney Foundation, The Michael J. Fox Foundation, Parkinson’s Foundation, the Parkinson & Movement Disorder Alliance and the World Parkinson Coalition.
For more information about “Live Well. Do Tell.” and Framing OFF Through Art, visit LiveWellDoTell.org.
About Parkinson’s and OFF Periods
Parkinson’s is a progressive neurodegenerative disorder resulting from the gradual loss of certain neurons. These neurons are responsible for producing dopamine and that loss causes a range of symptoms including impaired movement, muscle stiffness and tremors. As Parkinson’s progresses, people are likely to experience OFF periods, which are characterized by the return of Parkinson’s motor and non-motor symptoms; these can occur even in the presence of regular maintenance therapy. Approximately one million people in the U.S. and 10 million people worldwide are living with Parkinson’s; approximately 40 percent of people with Parkinson’s in the U.S. are estimated to experience OFF periods.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. For more information on Acorda products and pipeline, visit: https://www.acorda.com/products.
This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: we may not be able to successfully market Inbrija or any other products under development; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could affect whether we have sufficient commercial supply of Inbrija to meet market demand; third party payers (including governmental agencies) may not reimburse for the use of Inbrija or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; competition for Inbrija, Ampyra and other products we may develop and market in the future, including increasing competition and accompanying loss of revenues in the U.S. from generic versions of Ampyra (dalfampridine) following our loss of patent exclusivity; the ability to realize the benefits anticipated from acquisitions, among other reasons because acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; we may need to raise additional funds to finance our operations and may not be able to do so on acceptable terms; the risk of unfavorable results from future studies of Inbrija (levodopa inhalation powder) or from our other research and development programs, or any other acquired or in-licensed programs; the occurrence of adverse safety events with our products; the outcome (by judgment or settlement) and costs of legal, administrative or regulatory proceedings, investigations or inspections, including, without limitation, collective, representative or class action litigation; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies.
These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.